Physician profile
Shannon Murphy
NPI 1740838945
$5,201.63
in general payments reported to CMS, 2019-2025
48 companies · $959 in 2025
The $959 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.32 · 2022: $2,329 · 2023: $712 · 2024: $1,187 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $791.22 | 2022-2025 | |
| Pfizer INC. | $607.81 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $435.59 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $396.74 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Acadia Pharmaceuticals INC | $276.60 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $257.53 | 2022 | |
| Novo Nordisk INC | $233.92 | 2023-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $173.15 | 2022 | |
| Argenx US, INC. | $147.06 | 2022 | |
| Amgen INC. | $141.78 | 2022-2025 | Repatha, Otezla, Repatha |
| Biogen, INC. | $137.75 | 2022 | |
| Lundbeck LLC | $134.52 | 2022-2024 | Vyepti |
| Glaxosmithkline, LLC. | $126.19 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Harmony Biosciences LLC | $109.50 | 2022 | |
| Janssen Pharmaceuticals, INC | $106.78 | 2022-2024 | Spravato |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.